Innate Pharma (IPHA) Retained Earnings (2017 - 2025)
Innate Pharma's (IPHA) quarterly Retained Earnings came in at -$449.7 million in Q4 2025, down 24.93% YoY from -$599.1 million in Q4 2024, and down 33376.05% on a QoQ basis from $1.4 million in Q2 2025.
Innate Pharma (IPHA) Retained Earnings (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Retained Earnings data on file, last reported at -$449.7 million in Q4 2025.
- Quarterly Retained Earnings fell 24.93% year-over-year to -$449.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$449.7 million (down 24.93% YoY) and the FY2025 annual result came in at -$449.7 million, down 24.93% from the prior year.
- Retained Earnings retreated to -$449.7 million in Q4 2025, from $1.4 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1.4 million in Q2 2025 to a low of -$449.7 million in Q4 2025.
- A 5-year average of -$115.9 million and a median of $451434.5 in 2021 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 282.33% in 2023, down 42505.35% in 2023.
- Tracing IPHA's Retained Earnings over 5 years: stood at $521650.8 in 2021, then soared by 60.18% to $835582.6 in 2022, then tumbled by 42505.35% to -$354.3 million in 2023, then fell by 1.6% to -$360.0 million in 2024, then dropped by 24.93% to -$449.7 million in 2025.
- The last three Retained Earnings figures came in at -$449.7 million (Q4 2025), $1.4 million (Q2 2025), and -$360.0 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | -449.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -449.75 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Dec 31, 2024 | -360.00 Mn |
| Jun 30, 2024 | 381,218.20 |
| Dec 31, 2023 | -354.33 Mn |
| Jun 30, 2023 | 1.16 Mn |
| Dec 31, 2022 | 835,582.59 |
| Jun 30, 2022 | 303,044.10 |
| Dec 31, 2021 | 521,650.75 |
| Jun 30, 2021 | 861,054.08 |
| Dec 31, 2020 | 423,262.90 |
| Jun 30, 2020 | -568.00 Mn |
| Dec 31, 2019 | -522,450.98 |
| Dec 31, 2018 | -157.47 Mn |
| Dec 31, 2017 | -121.98 Mn |